People who have Diabetes and are on insulin often undergo pain due to needle pricks to administer insulin. Although insulin pumps have brought immense relief in this matter, researchers are looking for ways to ease the life of people with Diabetes by finding an effective medication. Insulin icodec is newer basal insulin which could be administered once in a week. .The phase 2 trial, published in The New England Journal of Medicine, was conducted on 247 participants who were not on insulin previously and they were divided into two groups.The HbAlc of the participants was 7-9.5 per cent. One group received icodec once-weekly injection whereas the other group was administered with once-daily long-acting insulin glargine u 100. Mer 26 weeks of administration. the HbA le of people in the icodec group was lowered by 1.33 per cent whereas the glargine group had a1.15 per cent decrease in their HbAlc. Other conditions such as hypoglycemia and cognitive impairment were found to be low in both groups. The study has concluded that the effect of both medications on people with Type 2 Diabetes was the same.
People who have Diabetes and are on insulin often undergo pain due to needle pricks to administer insulin. Although insulin pumps have brought immense relief in this matter, researchers are looking for ways to ease the life of people with Diabetes by finding an effective medication. Insulin icodec is newer basal insulin which could be administered once in a week. .The phase 2 trial, published in The New England Journal of Medicine, was conducted on 247 participants who were not on insulin previously and they were divided into two groups.The HbAlc of the participants was 7-9.5 per cent. One group received icodec once-weekly injection whereas the other group was administered with once-daily long-acting insulin glargine u 100. Mer 26 weeks of administration. the HbA le of people in the icodec group was lowered by 1.33 per cent whereas the glargine group had a1.15 per cent decrease in their HbAlc. Other conditions such as hypoglycemia and cognitive impairment were found to be low in both groups. The study has concluded that the effect of both medications on people with Type 2 Diabetes was the same.
